IBEX Technologies Inc
XTSX:IBT

Watchlist Manager
IBEX Technologies Inc Logo
IBEX Technologies Inc
XTSX:IBT
Watchlist
Price: 1.44 CAD
Market Cap: 35.3m CAD

Relative Value

IBT doesn't have a meaningful market cap.

There is not enough data to reliably calculate the relative value of IBT.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

IBT Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
4.6
Median 5Y
3.1
Industry
8
vs History
vs Industry
Median 3Y
8.8
Median 5Y
8.8
Industry
23.5
vs History
vs Industry
Median 3Y
16
Median 5Y
11.2
Industry
21.9
vs History
vs Industry
Median 3Y
49.1
Median 5Y
31.3
Industry
24.3
vs History
vs Industry
Median 3Y
2.5
Median 5Y
2
Industry
3.2
vs History
vs Industry
Median 3Y
3.6
Median 5Y
2.1
Industry
8.1
vs History
vs Industry
Median 3Y
5.1
Median 5Y
3
Industry
10.1
vs History
vs Industry
Median 3Y
14.1
Median 5Y
7.8
Industry
5.9
vs History
vs Industry
Median 3Y
18.4
Median 5Y
9.5
Industry
6.2
vs History
vs Industry
Median 3Y
12.6
Median 5Y
8.1
Industry
7.7
vs History
vs Industry
Median 3Y
27.5
Median 5Y
16.1
Industry
6.3
vs History
vs Industry
Median 3Y
3.9
Median 5Y
3.1
Industry
5.6

Multiples Across Competitors

IBT Competitors Multiples
IBEX Technologies Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CA
IBEX Technologies Inc
XTSX:IBT
35.5m CAD 4.6 8.8 14.1 18.4
IL
Can Fite Biopharma Ltd
TASE:CANF
707T ILS 255 120 668.6 -17 520 045.9 -17 192 530.1 -17 154 260
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 036 074.3 -161 768.4 -196 438.5 -194 196.9
US
Abbvie Inc
NYSE:ABBV
390.6B USD 6.6 168.8 16.3 23.1
US
Amgen Inc
NASDAQ:AMGN
177.3B USD 4.9 25.3 18.2 18.2
US
Gilead Sciences Inc
NASDAQ:GILD
150.3B USD 5.1 18.4 12.3 12.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
119.9B USD 10.2 32.7 24.1 25.2
US
Epizyme Inc
F:EPE
94.1B EUR 2 069.8 -528.2 -575.1 -559.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
84.1B USD 6 18.7 17.8 20.2
AU
CSL Ltd
ASX:CSL
84.4B AUD 3.6 18.8 12.7 15.8
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
53.7B USD 16.7 1 229.1 166.4 201.8
P/S Multiple
Revenue Growth P/S to Growth
CA
IBEX Technologies Inc
XTSX:IBT
Average P/S: 26 287 170.1
4.6
N/A N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
255 120 668.6
140%
1 822 290.5
FR
Pharnext SCA
OTC:PNEXF
34 036 074.3
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.6
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.9
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.1
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10.2
10%
1
US
E
Epizyme Inc
F:EPE
2 069.8
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
6
6%
1
AU
CSL Ltd
ASX:CSL
3.6
5%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
16.7
46%
0.4
P/E Multiple
Earnings Growth PEG
CA
IBEX Technologies Inc
XTSX:IBT
Average P/E: 190.1
8.8
N/A N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -17 520 045.9 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -161 768.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
168.8
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
25.3
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
18.4
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
32.7
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -528.2 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.7
10%
1.9
AU
CSL Ltd
ASX:CSL
18.8
11%
1.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 229.1
N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CA
IBEX Technologies Inc
XTSX:IBT
Average EV/EBITDA: 35.2
14.1
N/A N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -17 192 530.1 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -196 438.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.3
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.2
11%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
12.3
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.1
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -575.1 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.8
11%
1.6
AU
CSL Ltd
ASX:CSL
12.7
8%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
166.4
N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CA
IBEX Technologies Inc
XTSX:IBT
Average EV/EBIT: 41.9
18.4
N/A N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -17 154 260 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 196.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.1
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.2
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.3
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.2
16%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -559.8 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
20.2
13%
1.6
AU
CSL Ltd
ASX:CSL
15.8
11%
1.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
201.8
N/A N/A